Summary: A simple NT treatment regimen has been in place since the ESC/ESH guidelines published in 2018. It was upheld in the 2023 ESH guidelines. This document emphasizes the complex pathogenesis of NT. Therefore, it recommends starting NT treatment with two groups of hypotensive drugs and, if target blood pressure values are not achieved, quickly adding a third drug. Current guidelines maintain and even more emphasize the role of compounded preparations (SPCs) at every step of NT therapy. As of 2018, a number of studies have been published to emphasize this even more strongly. The use of compounded preparations in the first step of NT therapy is known to achieve recommended blood pressure values in 2 out of 3 patients. In contrast, using SPCs based on three hypotensive drugs makes it possible to ensure adequate blood pressure control in 90% of patients. NT therapy must be simple, effective and safe, because only then will it be used by the patient long-term.